Abstract Details

Title Vitamin B12 Measurements in Parkinson's Disease Patients

Topic Movement Disorders

Presentation(s) P06 - (-)

Poster/Presentation
Number 093

Objective

Background BACKGROUND: Several recent reports have found lower levels of vitamin B12 in PD patients who have neuropathy or cognitive impairment.

Design/Methods DESIGN/METHODS: We reviewed records from all PD patients seen in our practice between April-September 2012. All met Gelb et al (1999) criteria for possible or probable PD. We excluded those with a prior diagnosis of vitamin B12 deficiency or gastrointestinal conditions associated with B12 deficiency. The B12 measurements were often performed as part of the initial evaluation for PD and/or to evaluate those who developed cognitive impairment or gait instability.

Results RESULTS: Of 232 consecutive Parkinson's disease patients, 155 (67%) had a least one measurement of vitamin B12. Of these, 15 (10%) had measurements below 300 ng/l (considered borderline low) and 8 (5%) had levels below the lower limit (211 ng/l). For 44 patients with a mean (sd) age of 69.5 (7.8), 2 measurements were available. In 39, there was a decline in B12, and in 4 patients, the level fell below 211 ng/l. We categorized our data according to the number of years between measurements and found a median difference of -2% for measurements taken within 2 years, -17% measured from 2-3 years, -27% measured from 3-4 years, and -32% for 4 or more years (p<.005, nonparametric test for trend based on the Wilcoxon rank sum test).

Conclusions CONCLUSIONS: In this PD cohort, low vitamin B12 levels were fairly common. In the subset that underwent 2 measurements, we found fairly dramatic declines in B12 that exceed the modest reductions observed in cross-sectional studies. Further study is warranted to examine these levels over time in an appropriate comparison group and to determine whether whether lower B12 levels are associated with increased morbidity.

Authors/Disclosures
Chadwick W. Christine, MD, FAAN PRESENTER	The institution of Dr. Christine has received research support from Michael J Fox Foundation for Parkinson's Research. The institution of Dr. Christine has received research support from Aspen Neurosciences. The institution of Dr. Christine has received research support from ASK BIo. The institution of Dr. Christine has received research support from Bayer.
Nancy K. Hills, PhD (University of California, San Francisco)	No disclosure on file
Patrick Vermersch (CHR de Lille)	Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AB Science. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS-Celgene. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ad Scientiam. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for La revue des microbiotes. The institution of Patrick Vermersch has received research support from Roche. The institution of Patrick Vermersch has received research support from Sanofi.

��ɫ��

��ɫ��